Related Experiment Video

Updated: Oct 4, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

[Effective treatment of cardiac failure with caposide at an outpatient clinic]

B Ia Bart, V N Larina, E N Dergunova

    Terapevticheskii Arkhiv
    |March 10, 2001
    PubMed

    Insights

    Long-term caposide use improved cardiac failure symptoms and quality of life in outpatients. This therapy showed no serious side effects, suggesting it as a potential first-line treatment.

    Area of Science:

    • Cardiology
    • Pharmacology

    Context:

    • Chronic cardiac failure (CCF) affects a significant patient population.
    • Long-term management of CCF requires effective and safe therapeutic options.

    Purpose:

    • To assess the efficacy and safety of long-term outpatient caposide administration in patients with chronic cardiac failure.
    • To evaluate caposide's impact on clinical symptoms, quality of life, and physical activity.

    Summary:

    • A study involving 74 patients with chronic cardiac failure (CCF) due to ischemic heart disease or dilated cardiomyopathy evaluated long-term outpatient caposide therapy.
    • Patients received individualized caposide doses, with outcomes assessed through clinical symptom changes, quality of life, and physical activity levels.
    • Results indicated significant improvements in clinical symptoms, functional class, exercise tolerance, and quality of life, with no serious adverse events reported.

    Impact:

    • Caposide demonstrates potential as a first-line therapy for outpatient management of chronic cardiac failure.
    • It can be used as monotherapy or as an adjuvant in combination treatments for CCF patients.
    • The findings support caposide's role in improving patient outcomes and well-being in chronic cardiac conditions.
    Abstract

    More Related Videos

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

    Published on: February 10, 2023

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...